Short Answer

Approval of cytisinicline for smoking cessation before October 1, 2026, is highly improbable given the anticipated NDA resubmission in Q4 2026, priced by the market at 1.0%.

1. Market Behavior & Drivers

This market's near-zero valuation reflects the FDA's decision to issue a Complete Response Letter (CRL) for cytisinicline on June 22, 2026. The letter, sent to developer Achieve Life Sciences, declined approval for the smoking cessation drug. The market, which began trading after this event, opened with the near-certainty of non-approval already priced in.
The FDA's rejection was based on manufacturing deficiencies, not on safety or efficacy concerns. However, the market has assigned a minimal probability that Achieve can resolve these issues and secure approval before the contract's expiration. The subsequent price action, a drift from 2% to 1%, occurred on very low volume, signaling a static consensus with no new information to challenge the post-CRL outlook.
  • Approval by July 1, 2027, is likely given the anticipated H1 2027 FDA decision.
  • Approval before October 1, 2026, is highly improbable due to a Q4 2026 resubmission target.
  • January 1, 2027, approval is less likely, requiring an exceptionally fast Class 1 review.

Who Wins and Why

Outcome Market Model Why
Before Oct 1, 2026 1.0% 0.8% An NDA resubmission in Q4 2026 makes approval before October 1, 2026, highly improbable.
Before Jan 1, 2027 13.0% 10.1% Approval before January 1, 2027, is at the earliest edge of Achieve Life Sciences' projected timeline.
Before Jul 1, 2027 40.0% 38.4% Achieve Life Sciences anticipates potential FDA approval in the first half of 2027, aligning with the market deadline.

Current Context

Cytisinicline lacks FDA approval for smoking cessation as of September 20, 2026. Achieve Life Sciences received a Complete Response Letter (CRL) from the FDA on June 22, 2026, declining approval for cytisinicline [1][2][3][4][5][6][7][8][9][10]. The CRL cited manufacturing-related issues at a third-party facility and incomplete product labeling [1][2][3][4][5][6][7][8]. The FDA raised no concerns regarding the drug's clinical efficacy or safety [1][2][3][4][5][6][7][8][10]. The FDA's official list of approvals for September 2026 does not include cytisinicline for smoking cessation [11].
Achieve Life Sciences targets a Q4 2026 resubmission for cytisinicline. The company transitioned manufacturing to a new U.S.-based partner, Adare Pharma Solutions, completing necessary technology transfer and qualification procedures [1][2][3][4][5][6][7][8][12][9][10]. Achieve Life Sciences plans to resubmit its New Drug Application (NDA) in the fourth quarter of 2026, anticipating potential FDA approval in the first half of 2027 [1][2][3][4][5][6][7][8][12][9][10].
Cytisinicline has Breakthrough Therapy status for vaping cessation. The FDA granted this designation for the separate indication of nicotine e-cigarette (vaping) cessation [1][6][7][8][12]. Achieve Life Sciences has completed a Phase 2 study for this indication [1][6][7][8][12]. A new Phase 3 trial, ORCA-V2, evaluating cytisinicline for vaping cessation, is currently underway with an estimated primary completion date of November 15, 2026 [13]. Despite multiple Phase 3 and other clinical trials for smoking and vaping cessation, cytisinicline remains an investigational product [14][15][16][17].
Sources (17)
  1. 1Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA - BioSpacebiospace.com
  2. 2FDA Rejects Cytisinicline NDA Over Manufacturing Issues, Not Safetyclinicaltrialvanguard.com
  3. 3FDA Issues Complete Response Letter for Cytisinicline NDA, Citing...ajmc.com
  4. 4FDA Rejects Cytisinicline NDA for Now, Requests Manufacturing Resolution - Pharmacallypharmacally.com
  5. 5FDA Declines to Approve Achieve Life Sciences' Cytisinicline for Smoking Cessation, Citing Manufacturing Issues Only - MedPath Trialtrial.medpath.com
  6. 6Achieve Life Sciences Receives Complete Response Letter from...achievelifesciences.com
  7. 7EX-99.1sec.gov
  8. 8Achieve Life Sciences Reports Second Quarter 2026 Financialglobenewswire.com
  9. 9US FDA declines to approve Achieve Life Sciences' smoking-cessation drug - AOLaol.com
  10. 10US FDA declines to approve Achieve Life Sciences' smoking...reuters.com
  11. 11Drugs@FDA: FDA-Approved Drugsaccessdata.fda.gov
  12. 12Achieve Life Sciences Announces Operational Progress Including...achievelifesciences.com
  13. 13Study Details | NCT07392125 | ClinicalTrials.gov - ClinicalTrials.govclinicaltrials.gov
  14. 14A Study of Cytisinicline for Smoking Cessation in Adult Smokersclinicaltrials.gov
  15. 15Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokersclinicaltrials.gov
  16. 16A Study of Cytisinicline for Vaping Cessation in Adult Smokersclinicaltrials.gov
  17. 17Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Doseclinicaltrials.gov

2. Price Chart

Historical Price (Probability)

Outcome probability
Date

3. Significant Price Movements

Notable price changes detected in the chart, along with research into what caused each movement.

📈 September 19, 2026: 86.0pp spike

Price increased from 8.0% to 94.0%

Outcome: Before Oct 1, 2026

What happened: The 86.0 percentage point spike on September 19, 2026, was primarily driven by speculative or misinformed news and/or social media activity, which appears to have coincided with and led the market movement. This activity incorrectly suggested imminent FDA approval for cytisinicline before October 1, 2026 [1][2]. However, the official company timeline indicates an NDA resubmission in Q4 2026 and potential approval in H1 2027, with the research explicitly stating the spike should not be interpreted as evidence of imminent FDA approval [1][2]. Therefore, social media was likely a contributing accelerant to a misleading narrative.
Sources (2)
  1. 1Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA:: Achieve Life Sciences, Inc. (ACHV)ir.achievelifesciences.com
  2. 2EX-99.1sec.gov

4. Market Data

Contract Snapshot

This market resolves to YES if the FDA approves cytisinicline for smoking cessation, and to NO if no such approval occurs. Resolution is determined by specific deadlines, with sub-markets addressing approval before October 1, 2026, before January 1, 2027, and before July 1, 2027. No special settlement conditions beyond the timing of FDA approval are explicitly stated in the provided content.

Available Contracts

Market options and current pricing

Outcome bucket Yes (price) No (price) Last trade probability
Before Oct 1, 2026 $0.08 $0.99 1%
Before Jan 1, 2027 $0.17 $0.92 13%
Before Jul 1, 2027 $0.97 $0.94 40%

Market Discussion

The FDA issued a Complete Response Letter (CRL) for cytisinicline’s smoking-cessation NDA on June 22, 2026, citing outstanding manufacturing observations and incomplete labeling, not deficiencies in clinical efficacy or safety [1]. Achieve Life Sciences intends to resubmit the NDA in Q4 2026 after resolving manufacturing issues, anticipating potential FDA approval in H1 2027 [1]. As of September 16, 2026, a market snapshot reported roughly 40% implied probability of approval before July 1, 2027, with traders characterizing the manufacturing (CMC) issue as the pivotal risk, despite Phase 3 trials supporting an approvable efficacy narrative [2].

Sources (2)
  1. 1Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA:: Achieve Life Sciences, Inc. (ACHV)ir.achievelifesciences.com
  2. 2Will the FDA approve cytisinicline for smoking cessation? - Kalshi Odds | CoinRithmcoinrithm.com

5. Trust Index

Octagon Trust Index Kalshi 69 Caution

Primary risk· Trade quality

How it adds up
Integrity80% of score85Strong
Trade quality20% of score4Avoid
Trust score69Caution

Weighted blend with hard caps — a critically weak safety pillar, or a severe trading anomaly, caps the total regardless of the rest. Full methodology · About the Trust Index

Trust profile
Integrity4 screens run · 6 don't apply
Market integrity
84Good

Outcome is hard to influence

No suspicious activity on any screen

Screened clean
Large tradesNo single trade dominates the tape. Clear
Thin-volume movesMoves carried volume Clear
Size patternsNo distribution read Clear
2 screens not run
Outcome control · doesn't apply to this market type
Thin-leg conviction · doesn't apply to this market type
Info fairness
80Good

Structural prior — no screens apply

No suspicious activity on any screen

Screened clean
Information exposureNo concentrated group can know the outcome materially early. Clear
4 screens not run
Move vs. catalyst · doesn't apply to this market type
Longshot repricing · doesn't apply to this market type
Pre-broadcast certainty · doesn't apply to this market type
Cross-venue timing · doesn't apply to this market type
Resolution quality
92Strong

Resolution mechanism is dependable

No suspicious activity on any screen

Resolution rules read: Clear

Liquidity
4Very thin

Hard to fill near the screen price

3 contracts · worst first

Before Oct 1, 20264
Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Book spread 699% vs realized 32%
Before Jul 1, 2027—
No recent trading to measure

No recent trading to measure

Before Jan 1, 2027—
No recent trading to measure

No recent trading to measure

Move quality
82Confirmed

Moves came with real volume

3 contracts · worst first

Before Oct 1, 202682
Confirmed · medium confidence

Volume confirms the move over 24h

Before Jul 1, 2027—
Only 0 candle closes

Only 0 candle closes

Before Jan 1, 2027—
Only 0 candle closes

Only 0 candle closes

Rule clarity
100Clear

Counts toward Resolution quality, not here

3 contracts · worst first

Before Jul 1, 2027100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before Jan 1, 2027100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before Oct 1, 2026100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Trade quality
4Avoid

Thin market — entering or exiting at fair value will be difficult.

Outcome quality 4 (notional-weighted)

Before Jul 1, 2027Primary–Market scoreLiquidity–Move quality–Rule clarity100
Why this score
Liquidity
No recent trading to measure

No recent trading to measure

Move quality
Only 0 candle closes

Only 0 candle closes

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before Jan 1, 2027–Market scoreLiquidity–Move quality–Rule clarity100
Why this score
Liquidity
No recent trading to measure

No recent trading to measure

Move quality
Only 0 candle closes

Only 0 candle closes

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before Oct 1, 20264Market scoreLiquidity4Move quality82Rule clarity100
Why 4
Liquidity
4 · Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Book spread 699% vs realized 32%
Move quality
82 · Confirmed · medium confidence

Volume confirms the move over 24h

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear

underwriting_v1.4 · computed Sep 20, 2026

6. What are the key procedural milestones and expected FDA response times for Achieve Life Sciences' NDA resubmission in Q4 2026?

NDA Resubmission TargetQ4 2026 [1][2][3][4]
Potential FDA Approval TargetFirst half of 2027 [1][3][4][5]
Date of Complete Response LetterJune 22, 2026 [1][3][4][5]
Achieve Life Sciences received a Complete Response Letter (CRL) from the FDA for its cytisinicline New Drug Application (NDA) on June 22, 2026 [1][3][4][5]. The CRL primarily cited manufacturing deficiencies at a third-party facility and issues with incomplete final product labeling [1][3][4][5]. Importantly, the FDA did not identify any deficiencies related to the clinical efficacy or safety aspects of cytisinicline [1][3][4][5].
In response to the CRL, Achieve has addressed deficiencies and plans to resubmit its NDA in Q4 2026. Achieve has transitioned its commercial manufacturing operations for cytisinicline to Adare Pharma Solutions [1][2][3][4]. The company has also completed the analytical method technology transfer, produced an engineering batch, and qualified necessary testing procedures [1][2][3][4]. Achieve Life Sciences aims to resubmit its cytisinicline NDA in the fourth quarter of 2026 [1][2][3][4], with a target for potential FDA approval in the first half of 2027 [1][3][4][5]. A prediction market concerning FDA approval for cytisinicline for smoking cessation is set to resolve on January 1, 2027 [6][7].
Sources (7)
  1. 1FDA Issues CRL for Cytisinicline NDA for Smoking Cessationhcplive.com
  2. 2Achieve Life Sciences Shifts to Adare for Cytisinicline Manufacturingpharmanow.live
  3. 3Achieve Life Gets FDA CRL on Cytisinicline NDA | ACHV Stock Newsstocktitan.net
  4. 4FDA Rejects Cytisinicline NDA Over Manufacturing Issues, Not Safetyclinicaltrialvanguard.com
  5. 5US FDA declines to approve Achieve Life Sciences' smoking...reuters.com
  6. 6Will the FDA approve cytisinicline for smoking cessation? - Kalshi Odds | CoinRithmcoinrithm.com
  7. 7Will the FDA approve cytisinicline for smoking cessation? - Kalshi noteringen | CoinRithmcoinrithm.com

7. What specific evidence confirms Achieve Life Sciences and Adare Pharma Solutions have resolved the manufacturing issues cited in the FDA's June 2026 Complete Response Letter?

Reason for FDA CRLManufacturing-related cGMP observations and incomplete final product labeling (June 2026) [1][2][3][4]
New ManufacturerAdare Pharma Solutions [1][3][4][5]
Planned NDA ResubmissionFourth quarter of 2026 [1][3][4][5]
The FDA's 2026 CRL cited manufacturing and labeling deficiencies for cytisinicline. The June 2026 Complete Response Letter (CRL) was issued due to manufacturing-related current Good Manufacturing Practice (cGMP) observations at a previous third-party facility, along with incomplete final product labeling [1][2][3][4]. Notably, the letter did not identify any deficiencies related to the clinical efficacy or safety of the drug [1][2][3][4].
Achieve Life Sciences transitioned manufacturing to Adare Pharma Solutions to resolve these concerns. To address the issues outlined in the CRL, Achieve Life Sciences has moved its manufacturing operations to Adare Pharma Solutions [1][3][4][5]. At the Adare facility, Achieve Life Sciences has completed the analytical method technology transfer, successfully manufactured an engineering batch, and fully qualified all necessary testing procedures [1][3][4][5].
Resubmission is planned, but explicit resolution evidence is not currently available. Achieve Life Sciences intends to resubmit its New Drug Application (NDA) in the fourth quarter of 2026, with Adare Pharma Solutions designated as its primary manufacturer [1][3][4][5]. Potential FDA approval for cytisinicline is anticipated in the first half of 2027 [1][3][4][5]. However, the provided facts do not contain explicit evidence confirming that the manufacturing issues cited in the FDA's Complete Response Letter have been fully resolved [1][3][4][5].
Sources (5)
  1. 1Achieve Life Sciences Receives Complete Response Letter from...ir.achievelifesciences.com
  2. 2FDA Issues Complete Response Letter for Cytisinicline NDA, Citing...ajmc.com
  3. 3Achieve Life Sciences Q2 loss widens, boosts cash | ACHV 8-K Filingstocktitan.net
  4. 4US FDA declines to approve Achieve Life Sciences' smoking...reuters.com
  5. 5FDA Issues CRL To Achieve Life Sciences For Cytisinicline NDA Over CGMP Manufacturing Concernsrttnews.com

8. How does cytisinicline's clinical profile from its Phase 3 trials compare to the FDA-approved therapy varenicline (Chantix) on key efficacy and safety endpoints?

EfficacyComparable to varenicline for smoking cessation [1][2][3]
Long-term AbstinenceSome studies suggest superior rates for cytisinicline [1][2][3]
Safety ProfileSignificantly more favorable than varenicline, especially for GI side effects [1][2][3]
Cytisinicline demonstrates comparable efficacy to varenicline for smoking cessation. Clinical evidence indicates that cytisinicline is similarly effective in helping individuals quit smoking, with some studies also suggesting potentially superior long-term abstinence rates when compared to varenicline [1][2][3].
Cytisinicline exhibits a more favorable safety profile than varenicline. A significant improvement in safety has been observed with cytisinicline, particularly concerning a reduction in gastrointestinal side effects, such as nausea, which are commonly associated with varenicline [1][2][3].
Sources (3)
  1. 1Comparative Effectiveness of Cytisinicline and Varenicline...jheor.org
  2. 2D102-18 Comparative Effectiveness of Cytisinicline and Varenicline...academic.oup.com
  3. 3Institute for Clinical and Economic Review Publishes Evidence...icer.org

9. How might the results of the ORCA-V2 vaping cessation trial, expected in late 2026, influence the FDA's review of the smoking cessation NDA?

ORCA-V2 Primary CompletionNovember 2026 [1]
Smoking Cessation NDA Resubmission TargetQ4 2026 [2][3]
FDA Approval Probability (before Jan 1, 2027)11% [4][5]
The ORCA-V2 trial for vaping cessation is distinct from the smoking cessation NDA. This trial, which evaluates cytisinicline for vaping cessation, operates as a separate program from the smoking cessation New Drug Application (NDA). The primary completion of the ORCA-V2 trial is anticipated in November 2026, and its results are not expected to directly influence the resubmission of the smoking cessation NDA [1][6].
FDA's Complete Response Letter cited manufacturing issues for smoking cessation NDA. The FDA issued a Complete Response Letter (CRL) for the cytisinicline smoking cessation NDA on June 22, 2026. The letter cited manufacturing deficiencies at a third-party facility and incomplete labeling as reasons for the CRL, but did not express concerns regarding clinical efficacy or safety [2][3]. Achieve Life Sciences plans to resubmit the NDA in the fourth quarter of 2026, with a potential FDA approval targeted for the first half of 2027 [2][3]. Prediction markets currently indicate a low probability of 11% for FDA approval for smoking cessation before January 1, 2027, reflecting the impact of the June 2026 CRL [4][5].
Sources (6)
  1. 1Study Details | NCT07392125 | ClinicalTrials.gov - ClinicalTrials.govclinicaltrials.gov
  2. 2FDA Issues Complete Response Letter for Cytisinicline NDA, Citing...ajmc.com
  3. 3FDA Issues CRL to Cytisinicline for Smoking Cessationpatientcareonline.com
  4. 4Will the FDA approve cytisinicline for smoking cessation? - Kalshikalshi.com
  5. 5Will the FDA approve cytisinicline for smoking cessation? - Kalshi Odds | CoinRithmcoinrithm.com
  6. 6Achieve Life Sciences (ACHV) Corporate presentation Summaryquartr.com

10. What historical precedents from the FDA in 2024-2026 indicate the likely approval timeline for an NDA resubmitted after a manufacturing-only CRL?

Class 1 Resubmission Review Goal2 months [1][2][3][4]
Class 2 Resubmission Review Goal6 months [1][2][3][4]
Achieve Life Sciences Cytisinicline Potential ApprovalFirst half of 2027 [5]
FDA resubmissions are classified into Class 1 and Class 2 for review timelines. Class 1 resubmissions are for minor issues, aiming for a two-month review period, while Class 2 addresses more substantial concerns, targeting a six-month review [1][2][3][4]. Complete Response Letters (CRLs) solely related to manufacturing deficiencies, such as cGMP observations, typically fall into either of these categories, depending on the extent of necessary remediation and verification [1][2][3][4].
Achieve Life Sciences anticipates approval for cytisinicline following a specific 2026 CRL. On June 22, 2026, the company received a Complete Response Letter for cytisinicline, which cited manufacturing (cGMP) observations and labeling issues [5]. Notably, the CRL did not identify any deficiencies related to the drug's clinical efficacy or safety [5]. Achieve Life Sciences plans to resubmit its New Drug Application (NDA) for cytisinicline during the fourth quarter of 2026, with potential FDA approval projected for the first half of 2027 [5].
Sources (5)
  1. 1[PDF] SOPP 8405.1: Procedures for Resubmissions to an Application or...fda.gov
  2. 2FDA CRL: What It Means & What Happens Next - CASRAIcasrai.org
  3. 3What is a Complete Response Letter? - Avalere Health Advisoryadvisory.avalerehealth.com
  4. 4Complete Response Letter: FDA CRL Response Guide (May 2026)assyro.com
  5. 5Smoking Cessation - TeleDirectMDteledirectmd.com

11. What Could Change the Odds

Key Catalysts

As of September 20, 2026, cytisinicline is not FDA-approved for smoking cessation in the United States [1][2][3][4][5]. Achieve Life Sciences received a Complete Response Letter (CRL) from the FDA on June 22, 2026, declining approval due to manufacturing-related observations at a third-party facility and incomplete product labeling [1][3][4][5][6]. No deficiencies were identified regarding clinical efficacy or safety [1][3][4][5][6]. Cytisinicline is not FDA-approved for vaping cessation as of September 20, 2026 [7]. The FDA acknowledged cytisinicline as a potentially promising treatment for nicotine dependence, particularly for vaping cessation, a segment currently without an FDA-approved medication [7].
Achieve Life Sciences has transitioned manufacturing to Adare Pharma Solutions [1][2][3][4][5][8]. The company plans to resubmit its New Drug Application (NDA) in the fourth quarter of 2026, with potential FDA approval anticipated in the first half of 2027 [1][2][3][4][5][8].
Achieve Life Sciences is conducting clinical trials for cytisinicline [9][10]. A Phase 3 trial for vaping cessation (ORCA-V2) began in May 2026 and is expected to have primary results by November 2026 [9][10]. The company has completed multiple Phase 3 trials (ORCA-2, ORCA-3) evaluating cytisinicline for smoking cessation [11][12][13].

Key Dates & Catalysts

  • Expiration: October 08, 2026
  • Closes: July 01, 2027
Sources (13)
  1. 1Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA - BioSpacebiospace.com
  2. 2FDA Rejects Cytisinicline NDA Over Manufacturing Issues, Not Safetyclinicaltrialvanguard.com
  3. 3FDA Issues Complete Response Letter for Cytisinicline NDA, Citing...ajmc.com
  4. 4FDA Rejects Cytisinicline NDA for Now, Requests Manufacturing Resolution - Pharmacallypharmacally.com
  5. 5FDA Declines to Approve Achieve Life Sciences' Cytisinicline for Smoking Cessation, Citing Manufacturing Issues Only - MedPath Trialtrial.medpath.com
  6. 6US FDA declines to approve Achieve Life Sciences' smoking...reuters.com
  7. 7FDA Direct: These 9 Drugs Were Awarded National Priority Vouchersfda.gov
  8. 8Achieve Life Sciences Announces Operational Progress Including...ir.achievelifesciences.com
  9. 9Study Details | NCT07392125 | ClinicalTrials.gov - ClinicalTrials.govclinicaltrials.gov
  10. 10Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokersclinicaltrials.gov
  11. 11A Study of Cytisinicline for Smoking Cessation in Adult Smokersclinicaltrials.gov
  12. 12A Second Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokerscdn.clinicaltrials.gov
  13. 13A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokerscdn.clinicaltrials.gov

13. Historical Resolutions

Historical Resolutions: 7 markets in this series

Outcomes: 7 resolved YES, 0 resolved NO

Recent resolutions:

  • KXFDAAPPROVE-CAM-28JAN01: YES (Sep 08, 2026)
  • KXFDAAPPROVE-CAM-27JAN01: YES (Sep 08, 2026)
  • KXFDAAPPROVE-CAM-26OCT01: YES (Sep 08, 2026)
  • KXFDAAPPROVE-GED-27JUL01: YES (Jul 14, 2026)
  • KXFDAAPPROVE-GED-27JAN01: YES (Jul 14, 2026)